Appleton Partners’s Amneal Pharmaceuticals AMRX Stock Holding History

Appleton Partners’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-35,475	Closed	-$254K	–	279
2019 Q2	$254K	Buy	+35,475	New	+$363K	0.03%	253

Other funds holding AMRX

Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return

TGHSA

TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Appleton Partners's AMRX Position: Q3 2019 in Review

Appleton Partners sold out of Amneal Pharmaceuticals (AMRX) in Q3 2019, closing a stake of 35,475 shares — an estimated $254K sold.

Appleton Partners first reported a position in AMRX in Q2 2019 and held it in 1 quarter. The position peaked at $254K in Q2 2019. 121 funds tracked by Wall St. Rank hold AMRX as of Q3 2019.

Appleton Partners reported no remaining Amneal Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Appleton Partners sold 35,475 Amneal Pharmaceuticals shares in Q3 2019, an estimated $254K.
Appleton Partners first reported a position in Amneal Pharmaceuticals in Q2 2019 and held it in 1 quarter.
Appleton Partners's Amneal Pharmaceuticals position peaked at $254K in Q2 2019.
121 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2019.

Based on Appleton Partners's 13F filing for Q3 2019, filed 4 Nov 2019.